Aldagen
Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD100—151m (Dealroom.co estimates Apr 2008.)
Durham North Carolina (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$6.0m | Series A | ||
$4.9m | Series B | ||
$14.3m | Series C | ||
$9.0m | Series C | ||
$18.4m | Series D | ||
N/A | $7.3m | Debt | |
N/A | $1.1m | Debt | |
N/A | $585k | Debt | |
Total Funding | CAD71.7m |
Recent News about Aldagen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.